DOCSLIB.ORG

Promotive Effects of Steroids and Bile Acids on Hepatocarcinogenesis Initiated by Diethylnitrosamine1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Promotive Effects of Steroids and Bile Acids on Hepatocarcinogenesis Initiated by Diethylnitrosamine1 [CANCER RESEARCH 42, 2426-2428, June 1982] 0008-5472/82/0042-OOOOS02.00 Promotive Effects of Steroids and Bile Acids on Hepatocarcinogenesis Initiated by Diethylnitrosamine1 Ross G. Cameron,2 Katsumi Imaida, Hiroyuki Tsuda, and Nobuyuki Ito3 First Department of Pathology, Nagoya City University Medical School, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467, Japan ABSTRACT hepatocarcinogens on the liver in a short period, i.e., 8 weeks (7) or 12 weeks (19). Most of the hepatocarcinogens tested The ability of four steroids and three bile acids to promote enhanced the development of hyperplastic nodules in the liver, the appearance of hyperplastic foci and hyperplastic nodules and this process was enhanced in some cases by partial initiated by diethylnitrosamine (DEN) in the liver of male Fischer hepatectomy during the promotion phase (7). rats was tested and compared with that of the known promoter In this work, we tested for the promoting ability in liver of 2 phénobarbital (PB, 0.05%) as a standard value. Two weeks groups of nonhepatocarcinogens, steroids and bile acids, using after a single dose of 200 mg of DEN per kg, the animals were a short-term assay procedure similar to that described by Ito ef exposed to test chemicals for 10 weeks. At 4 weeks following a/. (7). The promoting effects of the 4 steroids and 3 bile acids DEN, all treatment groups were subjected to partial hepatec- are tentatively compared with those of PB and the hepatocar- tomy. Of the steroids tested at the maximum tolerable doses, cinogen 3'-Me-DAB given in the diet at conventional doses of as determined in preliminary experiments, ethinyl estradici was 0.05 and 0.06%, respectively. the most potent promoter, inducing more hyperplastic nodules than did PB and almost 50% less y-glutamyl transpeptidase- MATERIALS AND METHODS positive foci. However, y-glutamyl transpeptidase-positive foci induced by ethinyl estradiol were twice the average size as Animals and Diet. Male Fischer 344 rats (Charles River Japan, Inc., those induced by PB. The steroids testosterone, cortisone, and Kanagawa, Japan) weighing 120 to 150 g were first kept for 1 week dexamethasone induced more foci than did DEN alone, but few on basal diet (Oriental M, Oriental Yeast Co., Tokyo, Japan) to accli matize them to the 12-hr-light, 12-hr-dark cycle used. All animals were if any hyperplastic nodules. Deoxycholic acid was the most fasted for 18 hr prior to sacrifice. potent promoter of the bile acids tested, inducing 3 to 4 times Chemicals. Chemicals were of the purest grades available commer more hyperplastic nodules than did PB and more y-glutamyl cially and were obtained from the following sources: cortisone, dexa transpeptidase-positive foci, which were 5 times larger on the methasone, lithocholic acid, and deoxycholic acid, from Sigma Chem average than those induced by PB. The other bile acids tested, ical Co., St. Louis, Mo.; ethinyl estradiol, testosterone, 3'-Me-DAB, lithocholic acid and taurine, induced slightly more foci than did and DEN, from Tokyo Chemical Industry Co., Ltd., Tokyo, Japan; DEN alone but no hyperplastic nodules. These findings suggest taurine, from Katayama Chemical Co., Osaka, Japan; and PB, from that ethinyl estradiol and deoxycholic acid are relatively strong Iwaki Seiyaku Co., Tokyo, Japan. promoters of the appearance of preneoplastic lesions in he- Experimental Design. Fifteen animals were allotted to each of Groups 1 to 9 (A-B) and 20 animals to Group 10 (Table 1). The animals patocarcinogenesis. in Groups 1A to 9A and Group 10 were given a single i.p. injection of 200 mg of DEN per kg in 0.9% NaCI solution, a dose known to initiate INTRODUCTION hepatocarcinogenesis (3,14,15). Animals in Groups 1B to 9B received 0.9% NaCI solution i.p. After 2 weeks on basal diet, all groups received The initiation and promotion phases of liver carcinogenesis test chemicals in their diet for 10 weeks at the following doses: ethinyl are being clarified (3). The development of focal proliferations, estradiol, 10 ppm; testosterone, 500 ppm; cortisone, 10 ppm; dexa namely, hyperplastic foci or histochemical y-GT"-positive foci, methasone, 0.5 ppm; deoxycholic acid, 5000 ppm; lithocholic acid, and hyperplastic nodules in "initiated liver" have been referred 5000 ppm; taurine, 5000 ppm; PB, 500 ppm; and 3'-Me-DAB, 600 to as promotion (3). A variety of compounds show promoting ppm. Suitable doses of test chemicals were determined in preliminary ability after exposure to an "initiating" dose of a hepatocar- experiments; the highest doses permitting survival of the most animals cinogen. These chemicals include PB (11), dichlorodiphen- were used. The doses of PB and 3'-Me-DAB chosen were those yltrichloroethane (11), polychlorinated biphenyls (8, 13, 20), conventionally used. For Group 10, basal diet was given continuously 2,3,7,8-tetrachlorodibenzo-p-dioxine (12), 3-(3,5-dichloro- for 12 weeks after exposure to DEN. All groups were subjected to partial hepatectomy (5) in Week 4 after treatment with DEN or 0.9% phenyl)-5,5-dimethyloxazolinedione-2,4 (20), and mestranol NaCI solution to increase the proliferation of hepatocytes during the (22). promotion phase (7, 17). All animals were sacrificed at the end of Recently, several in vivo assays have been developed for Week 12. testing the promoting effects of hepatocarcinogens and non- Histological Examination and Quantitäten of Induced Lesions. At the time of sacrifice, the liver was excised and sections 1 to 2 mm 1 This work was supported in part by Grants-in-Aid 501061 and 501077 for thick were cut with a razor blade. Three sections, obtained from the Cancer Research from the Ministry of Education, Science and Culture and right posterior, right anterior, and caudate lobes, respectively, were Society for Promotion of Pathology, Nagoya, Japan. * Present address: Department of Pathology, Medical Sciences Building, Uni fixed in 10% formalin in phosphate buffer adjusted to pH 7.4, proc versity of Toronto, Toronto, Ontario, Canada M5S 1A8. essed, and stained with hematoxylin and eosin. A total of 4 sections, 3 To whom requests for reprints should be addressed. one each from the right posterior and caudate lobes and 2 from the 4 The abbreviations used are: >~GT. y-glutamyl transpeptidase; PB, phénobar right anterior lobes, were immediately fixed in ice-cold acetone for bital; 3'-Me-DAB, 3'-methyl-4-dimethyl-aminoazobenzene; DEN, diethylnitrosa histochemical examination of y-GJ activity by the method of Ogawa ef mine. Received May 20, 1981; accepted March 10, 1982. al. (9). The numbers, areas, and sizes of y-GT-positive foci were 2426 CANCER RESEARCH VOL. 42 Downloaded from cancerres.aacrjournals.org on October 2, 2021. © 1982 American Association for Cancer Research. Promotion of Hepatocarcinogenesis Table 1 Numbers, areas, and sizes of y-GT-positive foci and numbers of hyperplastic nodules induced by test compounds fociArea no. of of hyperplas cmSteroids1A.IB.2A.2B.3A.3B.4A.4B.DENGroup and treatmentDose (ppm)EffectiveratsNo./sq cmY-GT-positive(sq mm/sq cm)Size (sq mm/focus)No. tic nodules/sq estradiol90.9%—ethinyl ±05.3 0.5e00.2± ethinylestradiol*DENNaCI solution -» testosterone0.9%-» ±03.8 0.1rf00.2± testosteroneDENNaCI solution -» ±0.1d00.2 cortisone0.9%-» ±05.6 0.6± cortisoneDENNaCI solution —» ±0.l"012.7 ±02.16-'1.3e1.5"1.8eBiledexamethasone0.9%* -»dexamethasone101050050010100.50.514121514151211137.8NaCI solution acids5A.SB.6A.6B.7A.7B.DEN 2*0.1±11. acid0.9%—»deoxycholic ±0.5 3.6± deoxycholicacidDENNaCI solution -» ±3.5 0.190.3± 0.49±1.0"±1.9e± 1.1e00.1± acid0.9%•-•lithocholic ±03.9 acidDENNaCI solution -> lithocholic 0.000.1900.0400.0600.0400.480.110.0800.030±±±±±±±±0.06e0.020.01d0.010.2l'0.1190.04d0.013.701.000.60007.20.20000Positivetaurine0.9%-» ±09.8'0.591.1"1.4e1.5 ± NaCI solution —»taurine5000500050005000500050004e7e1415121523.8 controls8A.88.9A.9B.10.DENand negative PBa0.9%— 0.5e<0.01h28.0.3± ±<0.1*22.6 PBaDENNaCI solution -» 7.5e9.9± 3'-Me-DAB0.9%-. ±31.7 4.1e0.1± 3.6e± 3'-Me-DABDENNaCI solution -» ±2.2 -* basal diet8500500600600111013131914.4 ±2.6e5.4e9.8e0.91 ±0.10.09<0.031.260.320.04±h±±±0.03e0.27e0.12e0.022.108.811.21.2±1.0e±0.7±0.7 a Reported previously (1). " Mean ±S.D. 0 Significantly more than with DEN alone (Group 10); p < 0.001. " Significantly more than with DEN alone (Group 10); p < 0.01. e Deoxycholic acid (5000 ppm) in the diet was somewhat toxic, and many rats in Groups 5A and 5B died after partial hepatectomy. ' Significantly more than with DEN alone (Group 10); p < 0.05. 9 Six of 7 livers had y-GT-positive foci. Only 3 of 7 livers had hyperplastic nodules. h Two rats in this group had only one focus, each 0.03 sq mm. measured in y-GT-stained sections, as described previously (21 ), using nodules than did PB and 65% more y-GT-positive foci than did a color video image processor (VIP-21C, Olympus-lkegami Tsushin PB which were 5 times the average size of those with PB. The Co., Tokyo, Japan). Numbers of hyperplastic nodules were counted in other bile acids, lithocholic acid and taurine, induced fewer sections stained with hematoxylin and eosin. The criteria for the rec foci than did PB and no hyperplastic nodules. It is noteworthy ognition of hyperplastic nodules were as described previously (2, 3, 16).
Load more

Recommended publications
  • Does Your Patient Have Bile Acid Malabsorption?
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #198 NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #198 Carol Rees Parrish, MS, RDN, Series Editor Does Your Patient Have Bile Acid Malabsorption? John K. DiBaise Bile acid malabsorption is a common but underrecognized cause of chronic watery diarrhea, resulting in an incorrect diagnosis in many patients and interfering and delaying proper treatment. In this review, the synthesis, enterohepatic circulation, and function of bile acids are briefly reviewed followed by a discussion of bile acid malabsorption. Diagnostic and treatment options are also provided. INTRODUCTION n 1967, diarrhea caused by bile acids was We will first describe bile acid synthesis and first recognized and described as cholerhetic enterohepatic circulation, followed by a discussion (‘promoting bile secretion by the liver’) of disorders causing bile acid malabsorption I 1 enteropathy. Despite more than 50 years since (BAM) including their diagnosis and treatment. the initial report, bile acid diarrhea remains an underrecognized and underappreciated cause of Bile Acid Synthesis chronic diarrhea. One report found that only 6% Bile acids are produced in the liver as end products of of British gastroenterologists investigate for bile cholesterol metabolism. Bile acid synthesis occurs acid malabsorption (BAM) as part of the first-line by two pathways: the classical (neutral) pathway testing in patients with chronic diarrhea, while 61% via microsomal cholesterol 7α-hydroxylase consider the diagnosis only in selected patients (CYP7A1), or the alternative (acidic) pathway via or not at all.2 As a consequence, many patients mitochondrial sterol 27-hydroxylase (CYP27A1). are diagnosed with other causes of diarrhea or The classical pathway, which is responsible for are considered to have irritable bowel syndrome 90-95% of bile acid synthesis in humans, begins (IBS) or functional diarrhea by exclusion, thereby with 7α-hydroxylation of cholesterol catalyzed interfering with and delaying proper treatment.
    [Show full text]
  • Effect of Maternal Intrahepatic Cholestasis on Fetal Steroid Metabolism
    Effect of Maternal Intrahepatic Cholestasis on Fetal Steroid Metabolism Timo J. Laatikainen, … , Jari I. Peltonen, Pekka L. Nylander J Clin Invest. 1974;53(6):1709-1715. https://doi.org/10.1172/JCI107722. Research Article Estriol, estriol sulfate, progesterone, and 17 neutral steroid sulfates, including estriol precursors and progesterone metabolites, were determined in 27 cord plasma samples collected after pregnancies complicated by intrahepatic cholestasis of the mother. The levels of these steroids were compared with those in the cord plasma of 42 healthy controls. In the cord plasma, the steroid profile after pregnancies complicated by maternal intrahepatic cholestasis differed greatly from that seen after uncomplicated pregnancy. Two main differences were found. In the disulfate fraction, the concentrations of two pregnanediol isomers, 5α-pregnane-3α,20α-diol and 5β-pregnane-3α,20α-diol, were high after cholestasis. Other investigators have shown that, as a result of cholestasis, these pregnanediol sulfates circulate in greatly elevated amounts in the maternal plasma. Our results indicate that in cholestasis these steroids cross the placenta into the fetal compartment, where they circulate in elevated amounts as disulfates. Secondly, the concentrations of several steroid sulfates known to be synthesized by the fetus were significantly lower in the cholestasis group than in the healthy controls. This was especially true of 16α-hydroxydehydroepiandrosterone sulfate and 16α- hydroxypregnenolone sulfate. These results suggest that, in pregnancies complicated by maternal intrahepatic cholestasis, impairment of fetal steroid synthesis, and especially of 16α-hydroxylation, occurs in the fetal compartment. Thus, the changes in maternal steroid metabolism caused by cholestasis are reflected in the steroid profile of the fetoplacental circulation.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Protective Capabilities of Allopregnanolone Against Induced Toxicity in SH-SY5Y Cells Relative to Alzheimer´S Disease
    VT 2020 Protective capabilities of allopregnanolone against induced toxicity in SH-SY5Y cells relative to Alzheimer´s disease Mohamed Mustafa Degree Project in Pharmaceutical pharmacology, 30 hp, Spring semester 2020 Examiner: Mathias Hallberg Department of Pharmaceutical Biosciences Division for Pharmacology Faculty of Pharmacy Uppsala University Abstract When the brain is exposed to a traumatic injury, the brain produces high amounts of neurosteroids like allopregnanolone and progesterone which show protective and neurogenic capacities. Alzheimer’s disease patients also have lower amounts of these neurosteroids in brain tissue. Neurosteroids act on GABAA receptors and cholesterol receptors which is interesting since both the cholesterol transporter ApoE and excitotoxicity seems to be issues plaguing the patients. To study if there is a relationship between Alzheimer’s disease and neurosteroids, there are ongoing phase one studies but neurobiological studies are equally important in order to understand the mechanism. In this work protective capabilities of allopregnanolone on induced toxicity was investigated in human neuroblastoma SH-SY5Y cells. Protection and induced toxicity were assessed by studying cell viability with MTT assay. Toxins used were the oxidative stress inducing agent t-BHP, excitotoxic glutamate and amyloid β25-35. Previous studies have found allopregnanolone to induce neurogenesis, decrease ROS levels, inhibit apoptosis and to have immunoregulatory capabilities. The present study did see an increase in cell viability when treated to 1x10-8 M allopregnanolone but this effect was not observed when the concentration was increased further to 1x10-7 M and 1x10-6 M. When the SH-SY5Y cells were treated with toxins after pretreatment of allopregnanolone, additional decrease was seen when compared to cells only treated with toxins.
    [Show full text]
  • Regulation of Cytochrome P450 (CYP) Genes by Nuclear Receptors Paavo HONKAKOSKI*1 and Masahiko NEGISHI† *Department of Pharmaceutics, University of Kuopio, P
    Biochem. J. (2000) 347, 321–337 (Printed in Great Britain) 321 REVIEW ARTICLE Regulation of cytochrome P450 (CYP) genes by nuclear receptors Paavo HONKAKOSKI*1 and Masahiko NEGISHI† *Department of Pharmaceutics, University of Kuopio, P. O. Box 1627, FIN-70211 Kuopio, Finland, and †Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, NC 27709, U.S.A. Members of the nuclear-receptor superfamily mediate crucial homoeostasis. This review summarizes recent findings that in- physiological functions by regulating the synthesis of their target dicate that major classes of CYP genes are selectively regulated genes. Nuclear receptors are usually activated by ligand binding. by certain ligand-activated nuclear receptors, thus creating tightly Cytochrome P450 (CYP) isoforms often catalyse both formation controlled networks. and degradation of these ligands. CYPs also metabolize many exogenous compounds, some of which may act as activators of Key words: endobiotic metabolism, gene expression, gene tran- nuclear receptors and disruptors of endocrine and cellular scription, ligand-activated, xenobiotic metabolism. INTRODUCTION sex-, tissue- and development-specific expression patterns which are controlled by hormones or growth factors [16], suggesting Overview of the cytochrome P450 (CYP) superfamily that these CYPs may have critical roles, not only in elimination CYPs constitute a superfamily of haem-thiolate proteins present of endobiotic signalling molecules, but also in their production in prokaryotes and throughout the eukaryotes. CYPs act as [17]. Data from CYP gene disruptions and natural mutations mono-oxygenases, with functions ranging from the synthesis and support this view (see e.g. [18,19]). degradation of endogenous steroid hormones, vitamins and fatty Other mammalian CYPs have a prominent role in biosynthetic acid derivatives (‘endobiotics’) to the metabolism of foreign pathways.
    [Show full text]
  • Centene Employee
    Centene Employee PREFERRED DRUG LIST The Centene Employee Formulary includes a list of drugs covered by your prescription benefit. The formulary is updated often and may change. To get the most up-to-date information, you may view the latest formulary on our website at https://pharmacy.envolvehealth.com/members/formulary.html or call us at 1-844-262-6337. Updated: December 1, 2020 Table of Contents What is the Centene Employee Formulary?...................... .....................................................................ii How are the drugs listed in the categorical list?................................... .................................................ii How much will I pay for my drugs?.......................................................................................................ii How do I find a drug on the Drug List?..................................................................................................iii Are there any limits on my drug coverage?.............................................................................................iv Can I go to any pharmacy?......................................................................................................................iv Can I use a mail order pharmacy?...........................................................................................................v How can I get prior authorization or an exception to the rules for drug coverage?................................v How can I save money on my prescription drugs?.................................................................................v
    [Show full text]
  • Hepatic Bile Acids and Bile Acid-Related Gene Expression in Pregnant and Lactating Rats Qiong N
    Hepatic bile acids and bile acid-related gene expression in pregnant and lactating rats Qiong N. Zhu1, Hong M. Xie2, Dan Zhang1, Jie Liu1,3 and Yuan F. Lu1 1 Department of Pharmacology and Key Lab of Basic Pharmacology of Guizhou, Zunyi Medical College, Zunyi, China 2 Department of Gynaecology and Obstetrics, The Third AYliated Hospital of Zunyi Medical College, Zunyi, China 3 University of Kansas Medical Center, Kansas City, KS, USA ABSTRACT Background. Significant physiological changes occur during pregnancy and lacta- tion. Intrahepatic cholestasis of pregnancy (ICP) is a liver disease closely related to disruption of bile acid homeostasis. The objective of this study was to examine the regulation of bile acid synthesis and transport in normal pregnant and lactating rats. Materials and Methods. Livers from timed pregnant SD rats were collected on ges- tational days (GD) 10, 14 and 19, and postnatal days (PND) 1, 7, 14 and 21. Total bile acids were determined by the enzymatic method, total RNA was isolated and subjected to real time RT-PCR analysis. Liver protein was extracted for western-blot analysis. Results. Under physiological conditions hepatic bile acids were not elevated during pregnancy but increased during lactation in rats. Bile acid synthesis rate-limiting enzyme Cyp7a1 was unchanged on gestational days, but increased on PND14 and 21 at mRNA and protein levels. Expression of Cyp8b1, Cyp27a1 and Cyp7b1 was also higher during lactation. The mRNA levels of small heterodimer partner (SHP) and protein levels of farnesoid X receptor (FXR) were increased during pregnancy and lactation. Bile acid transporters Ntcp, Bsep, Mrp3 and Mrp4 were lower at gestation, Submitted 24 June 2013 but increased during lactation.
    [Show full text]
  • The Effects of Spironolactone in Preventing Bile Duct Ligation- Induced Hepatitis in a Rat Model
    Iranian Journal of Pharmaceutical Research (2021), 20 (2): 35-44 DOI: 10.22037/ijpr.2020.112488.13786 Received: September 2019 Accepted: April 2020 Original Article The Effects of Spironolactone in Preventing Bile Duct Ligation- induced Hepatitis in A Rat Model Ahmet Özer Şehirlia*, Azime Kökeşb, Ayliz Velioğlu-Öğünçc, Şermin Tetikd, Naziye Özkane, Şule Çetinele, Serkan Sayınerf and Gül Dülgerb aDepartment of Pharmacology, Faculty of Dentistry, Near East University, 99138 Nicosia, North Cyprus, Mersin 10, Turkey. bDepartment of Pharmacology, Faculty of Pharmacy, Marmara University, 34722 Istanbul, Turkey. cVocational School of Health-Related Professions, Marmara University, 34722 Istanbul, Turkey. dDepartment of Biochemistry, Faculty of Pharmacy, Marmara University, 34722 Istanbul, Turkey. eDepartment of Histology and Embryology, School of Medicine, Marmara University, 34722 Istanbul, Turkey. fDepartment of Biochemistry, Faculty of Veterinary Medicine, Near East University, 99138 Nicosia, North Cyprus, Mersin 10, Turkey. Abstract Cholestasis is associated with the accumulation of bile acids and bilirubin in the hepatocytes and leads to liver injury. Pregnane X Receptor (PXR) coordinates protective hepatic responses to toxic stimuli, and this receptor was reported to stimulate bile secretion by increasing MRP2 expression. Since PXR activators were reported to be anti-inflammatory in the liver, PXR was proposed as a drug target for the treatment of chronic inflammatory liver diseases. We investigated the potential protective effect of spironolactone
    [Show full text]
  • Prognostic and Mechanistic Potential of Progesterone Sulfates in Intrahepatic Cholestasis of Pregnancy and Pruritus Gravidarum
    AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 63, NO. 4, 2016 AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Prognostic and Mechanistic Potential of Progesterone Sulfates in Intrahepatic Cholestasis of Pregnancy and Pruritus Gravidarum Shadi Abu-Hayyeh,1* Caroline Ovadia,1* TinaMarie Lieu,2 Dane D. Jensen,2 Jenny Chambers,1,3 Peter H. Dixon,1,3 Anita Lovgren-Sandblom,€ 4 Ruth Bolier,5 Dagmar Tolenaars,5 Andreas E. Kremer,5,6 Argyro Syngelaki,7 Muna Noori,3 David Williams,8 Jose J.G. Marin,9 Maria J. Monte,9 Kypros H. Nicolaides,7 Ulrich Beuers,5 Ronald Oude-Elferink,5 Paul T. Seed,1 Lucy Chappell,1 Hanns-Ulrich Marschall,10 Nigel W. Bunnett,2,11 and Catherine Williamson1,3 A challenge in obstetrics is to distinguish pathological symptoms from those associated with normal changes of preg- nancy, typified by the need to differentiate whether gestational pruritus of the skin is an early symptom of intrahepatic cholestasis of pregnancy (ICP) or due to benign pruritus gravidarum. ICP is characterized by raised serum bile acids and complicated by spontaneous preterm labor and stillbirth. A biomarker for ICP would be invaluable for early diag- nosis and treatment and to enable its differentiation from other maternal diseases. Three progesterone sulfate com- pounds, whose concentrations have not previously been studied, were newly synthesized and assayed in the serum of three groups of ICP patients and found to be significantly higher in ICP at 9-15 weeks of gestation and prior to symp- tom onset (group 1 cases/samples: ICP n 5 35/80, uncomplicated pregnancy 5 29/100), demonstrating that all three progesterone sulfates are prognostic for ICP.
    [Show full text]
  • Pregnancy and Bile Acid Disorders
    Am J Physiol Gastrointest Liver Physiol 313: G1–G6, 2017. First published April 27, 2017; doi:10.1152/ajpgi.00028.2017. MINI-REVIEW Liver and Biliary Tract Physiology/Pathophysiology Pregnancy and bile acid disorders Vanessa Pataia, Peter H. Dixon, and Catherine Williamson Division of Women’s Health, King’s College London, London, United Kingdom Submitted 23 January 2017; accepted in final form 20 April 2017 Pataia V, Dixon PH, Williamson C. Pregnancy and bile acid disorders. Am J Physiol Gastrointest Liver Physiol 313: G1–G6, 2017. First published April 27, 2017; doi:10.1152/ajpgi.00028.2017.—During pregnancy, extensive adaptations in maternal metabolic and immunological physiology occur. Consequently, preexist- ing disease may be exacerbated or attenuated, and new disease susceptibility may be unmasked. Cholestatic diseases, characterized by a supraphysiological raise in bile acid levels, require careful monitoring during pregnancy. This review describes the latest advances in the knowledge of intrahepatic cholestasis of pregnancy (ICP), the most common bile acid disorder specific to pregnancy, with a focus on the disease etiology and potential mechanisms of ICP-associated adverse pregnancy outcomes, including fetal demise. The course of preexisting cholestatic conditions in pregnancy is considered, including primary sclerosing cholangitis, primary biliary cholangitis, biliary atresia, and Alagille syndrome. The currently accepted treatments for cholestasis in pregnancy and promising new therapeutics for the condition are described. bile acid; liver disease; cholestasis; pregnancy SUCCESSFUL PREGNANCY requires extensive physiological and ICP is associated with increased risk of spontaneous preterm metabolic adaptations to match the demands of the growing labor, fetal hypoxia, stillbirth, meconium-stained amniotic fetus.
    [Show full text]
  • PRODUCT MONOGRAPH Prteva-SPIRONOLACTONE/HCTZ
    PRODUCT MONOGRAPH PrTEVA-SPIRONOLACTONE/HCTZ Spironolactone and Hydrochlorothiazide Tablets, USP 25 mg of spironolactone and 25 mg of hydrochlorothiazide 50 mg of spironolactone and 50 mg of hydrochlorothiazide Aldosterone Antagonist with a Diuretic Teva Canada Limited Date of Revision: 30 Novopharm Court January 20, 2016 Toronto, Ontario Canada M1B 2K9 www.tevacanada.com Submission Control No: 190038 TEVA-SPIRONOLACTONE/HCTZ Page 1 of 39 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS .......................................................................................................... 9 DRUG INTERACTIONS ......................................................................................................... 15 DOSAGE AND ADMINISTRATION ..................................................................................... 19 OVERDOSAGE ....................................................................................................................... 20 ACTION AND CLINICAL
    [Show full text]
  • Contraceptives on Bile Lipid Composition
    Gut: first published as 10.1136/gut.24.3.253 on 1 March 1983. Downloaded from Guit, 1983, 24, 253-259 Effect of synthetic oestrogens and progestagens in oral contraceptives on bile lipid composition R H L DOWN, M J WHITING, J McK WATTS, AND W JONES From the Departments ofSurgery and Obstetrics and Gynaecology, Flinders Medical Centre, and Flinders University ofSouith Australia, NSW, Australia SUMMARY The prevalence of cholesterol gall stones in young women has increased since the introduction of oral contraceptives. The synthetic female sex hormones used in these preparations, increase the degree of cholesterol saturation in bile. To determine whether oestrogens, progestagens, or both, are responsible for the change in biliary cholesterol saturation index, a prospective randomised, controlled study was performed. A significant increase in the cholesterol saturation index of bile was observed when either 30 ug ethinyloestradiol plus 150 ,g norgestrel (p=001) or 50 ,ug ethinyloestradiol plus 250 gg norgestrel (p<0.01) were ingested daily for two months. No change in the cholesterol saturation index was observed when 30 ,g ethinyloestradiol alone, or 30 ,ug ethinyloestradiol plus 2.5 mg norethisterone were used. The mechanism for the increase in cholesterol saturation index did not appear to involve bile acid metabolism. These results indicate that the progestagen, norgestrel, and not as previously thought the oestrogen, ethinyloestradiol, is responsible for the increase in cholesterol saturation of bile which accompanies the use of oral contraceptives. http://gut.bmj.com/ Epidemiological studies'-"' have suggested that relative time periods of cholesterol unsaturation to there must be a causal relationship between female supersaturation during the day in favour of sex hormones and gall-stone disease.
    [Show full text]